GlobalData on MSN10h
FDA approves Syndax’s Revuforj to treat leukaemia
The US Food and Drug Administration (FDA) has approved Syndax Pharmaceuticals' Revuforj (revumenib) for treating relapsed or ...
Syndax Pharmaceuticals Gains Buy Rating Boost from Revuforj’s Early Approval and Strategic Launch Plan
Syndax Pharmaceuticals (SNDX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kelly ...
Syndax Pharmaceuticals Gains ‘Buy’ Rating Amidst Revuforj’s FDA Approval and Promising Market Prospects
Edward White, an analyst from H.C. Wainwright, reiterated the Buy rating on Syndax Pharmaceuticals (SNDX – Research Report). The associated ...
FiercePharma7h
Syndax ⁠scores FDA approval for Revuforj after it disappointed in another acute leukemia indication
The U.S. patient population for Revuforj in its approved indication is roughly 2,000 according to Syndax. KMT2A leukemias ...
Seeking Alpha6d
Syndax: Fall On NPM1m AML Data Of Revumenib Creates Buy Opportunity
Syndax Pharmaceuticals (NASDAQ:SNDX) just reported positive results from the phase 2 portion of its AUGMENT-101m trial evaluating the use of Revumenib for the treatment of patients with relapsed ...
Yahoo Finance13d
Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting
WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq:SNDX) today announced that multiple abstracts evaluating revumenib, an oral small molecule menin inhibitor, have been ...
Morningstar6d
Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib
WALTHAM, Mass., Nov. 12, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today ...
Nasdaq13d
Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting
"The data being presented this year at ASH demonstrate Syndax's commitment to develop revumenib as a practice-changing therapy for adult and pediatric patients with acute leukemias," said Neil ...
Benzinga.com6d
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer
Also Read: FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication Among the patients who achieved CR/CRh, 12 had a CR, and three had a CRh.
Stockhouse13d
Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting
WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq:SNDX) today announced that multiple abstracts evaluating revumenib, an oral small molecule menin inhibitor, have been ...
Investing5d
Goldman Sachs trims Syndax stock PT; confident in revumenib despite trial miss
On Wednesday, Goldman Sachs (NYSE:GS) updated its outlook on Syndax Pharmaceuticals (NASDAQ:SNDX), reducing the price target to $31 from the previous $33 while maintaining a Buy rating. The adjustment ...
Investing5d
Goldman Sachs trims Syndax stock PT; confident in revumenib despite trial miss
On Wednesday, Goldman Sachs updated its outlook on Syndax Pharmaceuticals (NASDAQ:SNDX), reducing the price target to $31 from the previous $33 while maintaining a Buy rating. The adjustment ...